Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Tumor Biology

Abstract 3849: Mast cell inhibition by Btk inhibitor PCI-32765 as a potential cancer therapy

Laura Soucek, Lee Honigberg, Roderik Kortlever, Joseph Buggy, Lamorna Swigart and Gerard I. Evan
Laura Soucek
1UCSF Comprehensive Cancer Ctr., San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lee Honigberg
2Pharmacyclics Inc, Sunnyvale, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Roderik Kortlever
1UCSF Comprehensive Cancer Ctr., San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joseph Buggy
2Pharmacyclics Inc, Sunnyvale, CA.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lamorna Swigart
1UCSF Comprehensive Cancer Ctr., San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerard I. Evan
1UCSF Comprehensive Cancer Ctr., San Francisco, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM10-3849 Published April 2010
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC

Abstract

An association between inflammation and cancer has long been recognized but the cause and effect relationship linking the two remains unclear. Myc is a pleiotropic transcription factor that is over-expressed in many human cancers and instructs multiple extracellular aspects of the tumor tissue phenotype, including remodeling of tumor stroma and angiogenesis. We have shown in a

β cell tumor model that Myc activation in vivo triggers rapid recruitment of mast cells to the tumor site, a recruitment that is absolutely required for macroscopic tumor expansion. Indeed, such tumors did not grow in mast cell deficient mice. Furthermore, treatment of established β cell tumors with cromolyn, a stabilizer that prevents mast cell degranulation, rapidly triggered hypoxia and cell death of tumor and endothelial cells. Inhibitors of mast cell function may therefore prove therapeutically useful in restraining expansion and survival of pancreatic cancer. However, such compounds have not yet been developed for systemic administration and applications in cancer therapy. In fact, there are no clinically effective mast-cell blockers. Therefore, we tested PCI-32765 (Pharmacyclics, Inc.), a Bruton's tyrosine kinase (BTK) inhibitor in clinical trials for B cell non-Hodgkin's lymphoma, for its ability to inhibit mast cell function and tumorigenesis in our mouse model of β cell neoplasia. Here we show that long term treatment with PCI-32765 prevents mast cell degranulation and causes tumor regression and vasculature collapse. Surprisingly, the compound also displays an unexpected anti-proliferative effect on tumor cells - but not surrounding normal tissue - which is still under investigation. Our results once more support the idea that mast cell inhibition could be beneficial in the treatment of insulinomas and possibly other pancreatic cancers and suggests that PCI-32765 could open the way to clinical studies assessing this potential.

Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 101st Annual Meeting of the American Association for Cancer Research; 2010 Apr 17-21; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2010;70(8 Suppl):Abstract nr 3849.

  • ©2010 American Association for Cancer Research
Back to top
Cancer Research: 70 (8 Supplement)
April 2010
Volume 70, Issue 8 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 3849: Mast cell inhibition by Btk inhibitor PCI-32765 as a potential cancer therapy
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 3849: Mast cell inhibition by Btk inhibitor PCI-32765 as a potential cancer therapy
Laura Soucek, Lee Honigberg, Roderik Kortlever, Joseph Buggy, Lamorna Swigart and Gerard I. Evan
Cancer Res April 15 2010 (70) (8 Supplement) 3849; DOI: 10.1158/1538-7445.AM10-3849

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 3849: Mast cell inhibition by Btk inhibitor PCI-32765 as a potential cancer therapy
Laura Soucek, Lee Honigberg, Roderik Kortlever, Joseph Buggy, Lamorna Swigart and Gerard I. Evan
Cancer Res April 15 2010 (70) (8 Supplement) 3849; DOI: 10.1158/1538-7445.AM10-3849
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Tumor Biology

  • Abstract SY34-04: Do we need to know what pO2 hypoxia is
  • Abstract SY28-04: Rational incorporation of novel agents into multimodality treatment of glioma and neuroblastoma
  • Abstract SY28-02: Connections in the BRCA1-BRCA2 pathway of homologous recombination: Implications for breast cancer development and treatment
Show more 3

Oral Presentations - Proffered Abstracts

  • Abstract LB-338: A critical evaluation of genomic data sharing: Barriers to accessing pediatric cancer genomic datasets: a Treehouse Childhood Cancer Initiative experience
  • Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study
  • Abstract LB-102: Landscape analysis of the initial data release from AACR Project GENIE
Show more 3

Proffered Oral Presentations - The Tumor Microenvironment and Therapeutic Strategies

  • Abstract 3847: Metastasizing host stromal cells potentiate colonization of metastatic tumors
  • Abstract 3846: Pleiotrophin in the tumor microenvironment induces expression of VEGFR2 on macrophages and promotes an anti-inflammatory phenotype
  • Abstract 3845: The normal breast microenvironment of premenopausal women differentially influences the behavior of breast cancer cells in vitro and in vivo
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement